EP0667163B1 - Pulver zur nasalen Verabreichung peptidischer oder proteinischer Arzneistoffe - Google Patents

Pulver zur nasalen Verabreichung peptidischer oder proteinischer Arzneistoffe Download PDF

Info

Publication number
EP0667163B1
EP0667163B1 EP94921840A EP94921840A EP0667163B1 EP 0667163 B1 EP0667163 B1 EP 0667163B1 EP 94921840 A EP94921840 A EP 94921840A EP 94921840 A EP94921840 A EP 94921840A EP 0667163 B1 EP0667163 B1 EP 0667163B1
Authority
EP
European Patent Office
Prior art keywords
group
powder composition
peptide
set forth
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP94921840A
Other languages
English (en)
French (fr)
Other versions
EP0667163A4 (de
EP0667163A1 (de
Inventor
Masahiko Dohi
Yoshihisa Nishibe
Yuji Makino
Yoshiki Suzuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teijin Ltd
Original Assignee
Teijin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Ltd filed Critical Teijin Ltd
Publication of EP0667163A1 publication Critical patent/EP0667163A1/de
Publication of EP0667163A4 publication Critical patent/EP0667163A4/de
Application granted granted Critical
Publication of EP0667163B1 publication Critical patent/EP0667163B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00485—Valves for air-conditioning devices, e.g. thermostatic valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Definitions

  • the present invention relates to a peptide proteinaceous drug nasal powder composition having an improved absorbency. More specifically, it relates to a peptide proteinaceous drug nasal powder composition, which is improved in absorption from the mucous membrane of the nasal cavity to the blood stream of the entire body by suppression of the decomposition of the peptide proteinaceous drug administered to the nasal cavity by an absorption accelerant having specified groups.
  • the nasal cavity has a well developed system of blood vessels in the mesothelium layer and is able to absorb a drug quickly and with little variation. Due to these advantages, the nasal administration method has come into attention. At the present time, however, sufficient absorption cannot be obtained, and therefore, various studies are under way to raise the absorbency.
  • Illum et al. Japanese National Disclosure (Kohyo) No. 2-503915 mentioned that effective protease inhibitors for nasal preparations in studies of rats, rabbits, and sheep were actinonin, amastatin, bestatin, chloroacetyl-HO-Leu-Ala-Gly-NH 2 , diprotin A and B, evelactone A and B, E- 64, H-(tBu)-Phe-Pro-OH, kallikrein inhibitor I, chymotrypsin inhibitor I, trypsin inhibitor III - 0, leupeptin, pepstatin, phosphoramidone, aprotinin, chymostatin, and benzamidine.
  • the present inventors confirmed by animal experiments using rabbits that in the nasal cavity of rabbits, salmon calcitonin, LHRH, insulin, and other peptide proteinaceous drugs were cleaved at the C terminal of the Leu in their primary structures and that the nasal absorbency of these is improved by administering them with a chymotrypsin inhibitor (for example, see Japanese Patent Application No. 5-130993 i.e., Japanese Unexamined Patent Publication No. 6-321804.
  • JP-04-300817 A1 discloses a composition for the oral cavity comprising tranexamic acid and peptides such as blood platelet-derived growth factor.
  • US-A-4,258,030 discloses a urokinase preparation for oral administration which is effective for remedy of thrombosis.
  • the preparation comprises urokinase and incorporated therein an enzyme inhibitor in the form of tranexamic acid.
  • the present invention provides a peptide proteinaceous drug nasal powder composition which, by combined use of a protease inhibitor, suppresses the degradation of the peptide proteinaceous drug in the human nasal cavity by the action of the enzyme, is improved in the nasal absorbency, and is safe to the body.
  • the present inventors found that a compound having the specific formula (II) suppressed the degradation of peptide proteinaceous drugs in the human nasal cavity and improves the nasal absorbency.
  • the compound having the formula (II), that is, the absorption accelerant for providing a peptide proteinaceous drug preparation which suppresses the degradation of peptide proteinaceous drug in the human nasal cavity by the action of the protease and improves the nasal absorbency may be said to be a compound where the aminomethyl group, aminoethyl group, and aminopropyl group have attached to them a cyclohexane ring or benzene ring that cannot cover these groups spatially due to the intermolecular electrostatic interaction or rigidity etc.
  • the absorption accelerant of the present invention are compounds in which the substituents and cyclohexane and benzene are substituted by other substituents, for example, chain (straight chain, branched) or cyclic saturated or unsaturated hydrocarbon groups etc. to the extent to which it is naturally assumed that these groups will not be covered spatially due to the intermolecular electrostatic interaction or rigidity etc.
  • the compound of formula (II) has a NH 2 -(CH 2 ) n -group. It is essential that this is bonded together with a cyclohexane ring or benzene ring.
  • the cyclohexane ring or benzene ring may have a substituent at the 3-, 4-, and/or 5-position three-dimensionally separated from the NH 2 -(CH 2 ) n -group.
  • the substituent is not particularly limited so long as it is a group which is stable as a preparation in the case of being made a powder and which poses no safety problem in terms of irritation etc. when administered to a human patient.
  • R 1 , R 2 , and R 3 are, independently, a group selected from a hydrogen atom, phosphoric acid group, cyano group, COOR, COR, OR', S(O) p R', NR'R", carbamoyl group, SO 2 NH 2 , and substitutable C 1 -C 20 hydrocarbon group, wherein R represents a hydrogen atom; C 1 -C 6 lower alkyl group which may be substituted; or R' and R" represent, independently, a hydrogen atom; C 1 -C 6 lower alkyl group which may be substituted, phenyl group which may be substituted, or C 7 -C 8 aralkyl group which may be substituted.
  • R 1 to R 3 as the C 1 -C 6 lower alkyl group, mention may be made of a methyl group, ethyl group, n-propyl group, i-propyl group, n-butyl group, i-butyl group, s-butyl group, t-butyl group, n-pentyl group, n-hexyl group, cyclopropyl group, and other straight chain or branched chain or cyclic alkyl groups. Among these, a methyl group, ethyl group, n-butyl group, and other C 1 -C 4 lower alkyl groups may be mentioned as being preferable. Further, as the C 7 -C 8 aralkyl group, mention may be made of a benzyl group and phenylethyl group.
  • the C 1 -C 20 hydrocarbon group means a saturated or unsaturated chain (straight chain or branched) or cyclic hydrocarbon group.
  • the C 1 -C 20 hydrocarbon group preferably, mention may be made of a C 1 -C 15 hydrocarbon group, more preferably a C 1 -C 10 hydrocarbon group.
  • COOR of the R 1 to R 3 mention may be made of a carboxyl group, methoxycarbonyl group, ethoxycarbonyl group, hexyloxycarbonyl group, and and as a specific example of the COR mention may be made of formyl group acetyl group, propionyl group, and
  • S(O) p R' mention may be made of a thiol group, sulfenic acid group, sulfinic acid group, sulfonic acid group, methylthiol group, isopropyl thiol group, isopropyl sulfinyl group, isopropyl sulfonyl group, pentyl sulfonyl group, phenyl thiol group, phenyl sulfonyl group, etc.
  • NR'R mention may be made of an amine group, dimethyl amine group, diethyl amine group, benzyl amine group, phenethyl amine group, etc.
  • OR' mention may be made of a hydroxyl group, methoxyl group, ethoxyl group, (n-, i-) propoxyl group, (n-, i-, s-, t-) butoxyl group, hexyloxyl group, cyclopropylmethyloxyl group, phenyloxyl group, phenethylloxyl group, etc.
  • the R 1 to R 3 of the present invention may, when having a C 1 -C 20 hydrocarbon group; C 1 -C 6 lower alkyl group, phenyl group, or C 7 -C 8 aralkyl group, further have substituents at these groups.
  • substituents mention may be made of the phosphoric acid group, cyano group, COOR, COR, OR', S(O) p R', NR'R", carbamoyl group, and SO 2 NH 2 exemplified as R 1 to R 3 .
  • n 1 or 2 in the above-mentioned formula (II)
  • Tranexamic acid has been known as a hemostyptic and is used at the time of abnormal bleeding caused by systemic hyperfibrinolysis. Its safety in the body has already been confirmed.
  • Rotraxate hydrochloride is known as a drug which has, as pharmaceutical actions, (1) an action of increasing the blood flow in the gastric mucous membrane and (2) an action of promoting the secretion of bicarbonate ion in the gastric mucous membrane and exhibits an anti-ulcer action that reinforces the function of protection of the gastric mucous membrane (see Japanese Examined Patent Publication (Kokoku) No. 60-36418).
  • Cetraxate hydrochloride is a drug which is used clinically for adaptation symptoms such as (1) lesions in the gastric mucous membrane (sores, bleeding, reddening, edema) due to the following ailments: acute gastritis and the acute exacerbated phase of chronic gastritis and (2) stomach ulcers (Nihon Iyakuhinshu 1993, p. 581, Yakuji Jihosha).
  • Mafenide acetate has been known in the past as an antibacterial agent and is effective for infection of wound surfaces by bacteria at the time of burns (Nihon Yakuhin Yoran, 5th edition, p. 1140, Yakuji Jihosha).
  • Dopamine hydrochloride is a drug which is used clinically for adaptation symptoms such as (1) acute circulatory insufficiency (cardiogenic shock, hemorraghic shock) and (2) acute circulatory insufficiency conditions (Nihon Iyakuhinshu 1993, p. 772, Yakuji Jihosha).
  • Tranexamic acid suppresses the enzymatic degradation of the peptide proteinaceous drug in the human nasal cavity, so it could be guessed that there is plasmin present in the human nasal cavity and that the plasmin cleaves down the peptide proteinaceous drug, but in the present invention the plasmin activity is low and, also, no effect of promoting nasal absorption was observed in by the ⁇ -amino caproic acid, which is a kind of plasmin inhibitor, so the possibility of plasmin playing a major part in the degradation of the peptide proteinaceous drug is denied.
  • a trypsin-like enzyme is present in the human nasal cavity.
  • the peptide proteinaceous drug administered in the nasal cavity is mainly cleaved by this enzyme. It is possible to improve the nasal absorbency of peptide proteinaceous drugs by administering a trypsin inhibitor in the human nasal cavity at the same time.
  • tranexamic acid, rotraxate hydrochloride, cetraxate hydrochloride, mafenide acetate, dopamine hydrochloride, and other compounds of the present invention have no trypsin inhibiting activity, but maintain a higher effect that the effect of promotion of the rate of nasal absorption of a trypsin inhibitor.
  • a trypsin-like enzyme exists in the human nasal cavity and the peptide proteinaceous drug administered in the nasal cavity is mainly broken down by that enzyme, but it is believed that the enzyme is restrained more effectively than a trypsin inhibitor by the compound of the present invention, such as tranexamic acid, rotraxate hydrochloride, cetraxate hydrochloride, mafenide acetate, dopamine hydrochloride, etc.
  • tranexamic acid, rotraxate hydrochloride, cetraxate hydrochloride, mafenide acetate, dopamine hydrochloride, and other compounds of the present invention can improve the stability of peptide proteinaceous drugs in the human nasal cavity and, accordingly, by administering them together with peptide proteinaceous drugs in the nasal cavity, can improve the nasal absorbency of the peptide proteinaceous drugs.
  • tranexamic acid used herein means trans-4-(aminomethyl) cyclohexane carboxylic acid, but in the present invention use may also be made of the cis-form, namely, cis-4-(aminomethyl) cyclohexane carboxylic acid.
  • the rotraxate hydrochloride means a hydrochloride of 3-((p-(trans-4-aminomethylcyclohexyl-carbonyl)phenyl)) propionic acid, but in the present invention, use may also be made of the cis-form, namely, a hydrochloride of 3-(p-(cis-4-aminomethylcyclohexyl-carbonyl)phenyl) propionic acid and also other pharmaceutically allowable salts.
  • cetraxate hydrochloride means a hydrochloride of trans-(4-aminomethyl) cyclohexane carboxylic acid p-(2-carboxyethyl)phenyl ester, but in the present invention, use may also be made of the cis-form, namely, cis-(4-aminomethyl) cyclohexane carboxylic acid p-(2-carboxy ethyl)phenyl ester and also other different pharmaceutically allowable salts.
  • mafenide acetate means an acetate of 4-(aminomethyl) benzenesulfamine, but in the present invention, use may also be made of other pharmaceutically allowable salts.
  • dopamine hydrochloride means a hydrochloride of 4-(2-aminoethyl)-1,2 benzenediol, but in the present invention, use may also be made of other pharmaceutically allowable salts.
  • the salt of the compound of the above formula (I) or (II) of the present invention means, for example, an acid addition salt, metal salt, or other pharmaceutically allowable salt.
  • a metal salt mention may be made of a sodium salt, potassium salt, and other alkali metal salt.
  • the acid of the acid addition salt is not limited so long as it gives a pharmaceutically allowable acid addition salt.
  • peptide proteinaceous drug mention may be made of at least one type of peptide proteinaceous drug selected from the group comprising calcitonins, somatostatin (GIF) and its derivatives, parathyroid hormones (PTH), substance P, platelet derived growth factors (PDGF), galanin, gastrin, neurokinins, interleukins, neurotensin, endo serine, growth hormone-releasing hormone (GHRH) and its derivatives, growth hormone releasing factor (GRF), luteinizing hormone-releasing hormone (LHRH) and its derivative, enkephalin and its derivatives, secretin, bradykinin and its derivatives, adrenocorticotrophic hormone (ACTH) and its derivatives, insulins, glucagon, insulin growth factor (IGF), calcitonin gene related peptide (CGRP), vasopressin and its derivatives, atrial natrium peptide (ANP), erythropoietin,
  • GRF parathyroid
  • peptide proteinaceous drugs of the present invention mention may be made of calcitonin, somatostatin (GIF), growth hormone releasing hormone (GHRH), luteinizing hormone-releasing hormone (LHRH), parathyroid hormone (PTH), or their derivatives.
  • GIF somatostatin
  • GHRH growth hormone releasing hormone
  • LHRH luteinizing hormone-releasing hormone
  • PTH parathyroid hormone
  • calcitonin is a peptide hormone which regulates the metabolism of calcium in the body. It works to obstruct the absorption of calcium in the bones and to cause the reabsorption of calcium released from the kidneys.
  • salmon calcitonin eel calcitonin
  • human calcitonin pig calcitonin
  • chicken calcitonin bovine calcitonin
  • sheep calcitonin rat calcitonin
  • use may be made of the derivatives of these calcitonins, for examle, elcatonin and other synthetic calcitonin and genetically engineered calcitonin.
  • Somatostatin is a peptide comprised of 14 amino acid residues which act on the pituitary of vertebrates to suppress the release of GH and TSH and PRL and suppress secretion of gastrin, motilin, secretin, digestive enzymes, gastric acids, etc. in the gastropancreatic system.
  • GH and TSH and PRL secretion of gastrin, motilin, secretin, digestive enzymes, gastric acids, etc. in the gastropancreatic system.
  • derivatives of somatostatin there are known for example ones like octoreotide acetate and other synthetic somatostatins wherein part of the amino acids are substituted with the D-form and several amino acids are removed to give 6 to 7 amino acid residues. In the present invention, each of these may also be used.
  • LHRH luteinizing hormone-releasing hormone
  • [D-Ser(t-Bu) 6 des-Gly 10 ethylamide] LHRH, [D-Ala-3(2-Naphtyl) 6 ] LHRH, [D-Leu 6 , des-Gly 10 ethylamide] LHRH, [D-Ser(t-Bu) 6 , aza-Gly 10 ] LHRH, [N-Ac-D-Nal(2) 1 , DpFPhe 2 , D-Pal(3) 3 , Lys(Nic) 5 , D-Lys(Nic) 6 , Lys(iPr) 8 , D-Ala 10 ] LHRH, and other synthetic LHRH and others with the 6-position Gly substituted with a D-form and others with the C-terminal glysine-amide substituted with alkylamine.
  • the growth hormone releasing hormone is a peptide which is comprised of 43 to 44 amino acid residues which act on the anterior pituitary of mammals and cause the release of growth hormones (GH).
  • GH growth hormones
  • human, rat, bovine, sheep, and pig types As the derivatives, there are known ones with the C-terminal taken and made (1-29)-NH 2 etc. In the present invention, each of these may also be used.
  • Parathyroid hormone is a peptide which is comprised of 84 amino acid residues which act on bone and kidney and promote reabsorption of Ca 2+ .
  • PTH 1-34 NH 2 which is comprised of 1 to 34 amino acid residues of the N terminal etc. In the present invention, each of these may also be used.
  • the absorption accelerant of the present invention As the combination of the absorption accelerant of the present invention and the peptide proteinaceous drug, mention may be made of the absorption accelerant having the above formula (I) or expressed by the formula (II) and a peptide proteinaceous drug.
  • an absorption accelerant of mafenide or its pharmaceutically allowable acid addition salts in particular, mafenide acetate, and, in this case, a particular, mafenide acetate, and, in this case, a peptide proteinaceous drug of, for example, the above illustrated salmon calcitonin and other calcitonins
  • the amount of the peptide proteinaceous drug in the present invention is the therapeutically effective amount.
  • the amount is specific to the different types of peptide proteinaceous drug.
  • the therapeutically effective amount is usually preferably the same amount 1 to 20 times the amount of the peptide proteinaceous drug administered by injection, more preferably 2 to 10 times the amount.
  • the amount of the absorption accelerant of the present invention is preferably approximately 0.1-10 parts by weight based on 1 part by weight of the therapeutically effective amount of the peptide proteinaceous drug, more preferably approximately 1 to 5 parts by weight, still more preferably 1 to 3 parts by weight.
  • the amounts and ratio in the case of mixing two or more types of absorption accelerants are not particularly limited, but the total amount is preferably in this range.
  • the peptide proteinaceous drug nasal powder of the present invention is produced by mixing one or more types of a fine powder peptide proteinaceous drug and the absorption accelerant of the present invention, for example, a water absorbing and water-insoluble base.
  • a water absorbing and water-insoluble base for example, a water absorbing and water-insoluble base.
  • the mixing is performed using a mortar, high speed mixer, or other usual mixer.
  • the water-absorbing and water-insoluble base spoken of here means something which has absorbency and insolubility on human nasal mucous membrane or in an environment close to that, that is, with respect to water of a pH of about 7.4 and a temperature of about 36°C to about 37°C.
  • water-absorbing and water-insoluble cellulose such as microcrystalline cellulose, ⁇ -cellulose, cross-linked sodium carboxymethylcellulose, and their derivatives
  • water-absorbing and water-insoluble gum such as arabia gum, tragacanth gum, glucomannan and their derivatives
  • cross-linked vinyl polymers such as polyvinylpolypyridone, cross-linked polyacrylic acid and its salt, cross-linked polyvinyl alcohol, polyhydroxyethylmethacrylate and their derivatives.
  • water-absorbing and water-insoluble cellulose is preferable, in particular, microcrystalline cellulose and its derivative are desirable.
  • a lubricant for example, mention may be made of talc, stearic acid and its salts, etc.; as a colorant, for example, mention may be made of copper chlorophyll, ⁇ -carotene, red No. 2, blue No. 1, etc.; as a preservative, for example, mention may be made of stearic acid, ascorbic acid stearate, etc.; as an antiseptic, for example, mention may be made of benzylkonium chloride and other quaternary ammonium compounds, paraoxybenzoic acid esters, phenols, chlorobutanol, etc.; and as deodorant, mention may be made for example of menthol, citrus fragrances, etc.
  • the peptide proteinaceous drug nasal powder of the present invention is usually administered in the nasal cavity by the following method. That is, a capsule filled with the powder to set for example in an exclusive spray apparatus possessing a needle, the needle is made to penetrate it to make fine holes at the top and bottom of the capsule, then air is fed by a rubber ball etc. to make the powder spray out.
  • the C end side of Lys of the peptide proteinaceous drug is first cleaved in a human nasal mucosal homogenate. From this, it is guessed that the protease which first cleaves the peptide proteinaceous drug in the human nasal cavity is a trypsin-like enzyme.
  • a refined trypsin (made by Wako Pure Chemical Industry) was used, instead of the human nasal mucosal homogenate solution, in the same procedures followed as in (1) to separate the degradation fragments of salmon calcitonin in the reaction liquid by HPLC.
  • the amino acid sequence was determined by an amino-acid sequencer. The results are shown in Table 2.
  • a homogenate solution was prepared from human nasal mucosa to give 1 mg/ml of protein.
  • synthesis substrates corresponding to the various proteases shown in Table 1 were added to 0.5 ml portions of the homogenate solution to give 0.1 mM concentrations.
  • the results were incubated at 37°C.
  • the amounts of the substrates remaining after a predetermined time were measured by HPLC to find the amounts of substrates cleaved and find the activity of the various proteases. The results are shown in Table 3.
  • Boc means a t-Butyloxycarbonyl group
  • Suc means a Succinyl group
  • Bz means a Benzyl group
  • MCA means 4-Methyl-Coumaryl-7-Amide.
  • a trypsin-like enzyme has a relatively high activity in human nasal mucosal homogenate, while plasmin has a considerably low activity.
  • plasmin has a considerably low activity.
  • the enzyme present in the human nasal mucosal homogenate is not trypsin itself. That is, it is guessed that in the human nasal cavity, peptide proteinaceous drugs are mainly cleaved down by enzymes which are not trypsin, but have trypsin-like activity.
  • a homogenate solution was prepared from human nasal mucosa to give 1 mg/ml of protein.
  • 0.25 ml portions of aqueous solutions (72 mM) of the different peptide proteinaceous drugs were added to 0.5 ml portions of the homogenate solution, 0.01 ml portions of aqueous solutions (72M) of different enzyme inhibitors or absorption accelerants of the present invention were added, and the results were incubated at 37°C.
  • the amounts of the peptide proteinaceous drug not yet cleaved after a predetermined time were measured by HPLC to find the amounts of decomposition.
  • the Aprotinin, Gabexate, ACA, and Tranexamic acid used were made by Wako Pure Chemical Industry, chymostatin was made by the Peptide Kenkyusho, TPCK and Thiorphan were made by Sigma Co., Pepstatin was made by Boehringer Mannheim Co., cetraxate hydrochloride was made by Daiichi Pharmaceutical Co., the rotraxate hydrochloride was synthesized and refined based on the description of Japanese Examined Patent Publication (Kokoku) No. 60-36418, the mafenide acetate was made by Tokyo Kasei Co., and the dopamine hydrochloride was made by Wako Pure Chemical Industry. Furthermore the benzylamine was made by Wako Pure Chemical Industry and the p-aminomethyl benzoic acid was made by Tokyo Kasei Co.
  • tranexamic acid which is not a trypsin inhibitor
  • other compounds of the present invention which are not trypsin inhibitors and are also not recognized as enzyme inhibitors, such as cyclohexane methylamine, cetraxate hydrochloride, rotraxate hydrochloride, benzylamine, p-aminomethyl benzoic acid, mafenide acetate, dopamine hydrochloride, etc.
  • the enzymes which cleave peptide proteinaceous drugs in human nasal cavities are trypsin-like enzymes having the characteristic of being remarkably restrained in activity by compounds of the present invention like tranexamic acid, cyclohexane methylamine, rotraxate hydrochloride, cetraxate hydrochloride, benzylamine, p-aminomethyl benzoic acid, mafenide acetate, and dopamine hydrochloride.
  • Salmon calcitonin in an amount of 40 ⁇ g, tranexamic acid 40 ⁇ g, microcrystalline cellulose 30 mg, and magnesium stearate 15 ⁇ g were mixed in a mortar to prepare a tranexamic acid-added calcitonin nasal powder.
  • the powder was weighed to give 100 IU (20 ⁇ g) of calcitonin, was packed in No. 2 capsules, then was administered to the right nasal cavities of three normal human volunteers by a Publizer (registered trademark, Teijin). After administration, 5 ml of blood was taken from a vein in the forearm every certain period and the concentration of salmon calcitonin in the plasma was measured by the RIA method. The results are shown in Fig. 1 by the time curve of the concentration of salmon calcitonin in the plasma.
  • Example 2 The same procedure was followed as in Example 1, except that 40 ⁇ g of tranexamic acid was not added, to prepare a tranexamic acid-free calcitonin nasal powder, the powder was weighed to give 100 IU (20 ⁇ g) of calcitonin and was packed in No. 2 capsules, then was administered to three normal human volunteers in the same way as in Example 1, then after a certain time the concentration of salmon calcitonin in the plasma was measured. The results are shown together in Fig. 1.
  • Example 1 The same procedure was followed as in Example 1, except that use was made of 0.4 mg of aprotinin instead of the 40 ⁇ g of tranexamic acid in Example 1, to prepare an aprotinin-added calcitonin nasal powder, the powder was administered to three normal human volunteers in the same way as in Example 1, then after a certain time the concentration of salmon calcitonin in the plasma was measured. The results are shown together in Fig. 1.
  • GHRH Somatorein acetate
  • tranexamic acid 1.0 mg microcrystalline cellulose 30 mg, and magnesium stearate 15 ⁇ g were mixed in a mortar to prepare a tranexamic acid-added GHRH nasal powder.
  • the powder was weighed to give a 1.0 mg amount of GHRH, was packed in No. 2 capsules, and was administered to the right nasal cavities of three normal human volunteers in the same way as in Example 1, then after a certain time the concentration of growth hormone (GH) in the plasma was measured. The results are shown together in Fig. 2 by the time curve of the concentration of GH in the plasma.
  • Example 2 The same procedure was followed as in Example 2, except that 1.0 mg of tranexamic acid was not added, to prepare a tranexamic acid-free GHRH nasal powder, the powder was weighed to give 1.0 mg of GHRH and was packed in No. 2 capsules, then was administered to three normal human volunteers in the same way as in Example 2, then after a certain time the concentration of GH in the plasma was measured. The results are shown together in Fig. 2.
  • Example 2 The same procedure was followed as in Example 2, except that use was made of 2.0 mg of gabexate mesylate instead of 1.0 mg of tranexamic acid, to prepare a gabexate mesylate-added GHRH nasal powder, the powder was administered to three normal human volunteers in the same way as in Example 2, then after a certain time the concentration of GH in the plasma was measured. The results are shown together in Fig. 2.
  • Deslorelin (LHRH derivative) in an amount of 0.2 mg, tranexamic acid 0.2 mg, microcrystalline cellulose 30 mg, and magnesium stearate 15 ⁇ g were mixed in a mortar to prepare a tranexamic acid-added LHRH derivative nasal powder.
  • the powder was weighed to give 1.0 mg of the LHRH derivative, was packed in No. 2 capsules, then was administered to the right nasal cavities of three normal human volunteers in the same way as in Example 1, then after a certain time the concentration of leuteinizing hormone (LH) in the plasma was measured. The results are shown in Fig. 3 by the time curve of the LH concentration in the plasma.
  • Example 3 The same procedure was followed as in Example 3, except that 0.2 mg of tranexamic acid was not added, to prepare a tranexamic acid-free LHRH derivative nasal powder, the powder was weighed to give 1.0 mg of LHRH derivative and was packed in No. 2 capsules, then was administered to three normal human volunteers in the same way as in Example 3, then after a certain time the concentration of GH in the plasma was measured. The results are shown together in Fig. 3.
  • Example 3 The same procedure was followed as in Example 3, except that use was made of 0.4 mg of aprotinin instead of 0.2 mg of tranexamic acid, to prepare an aprotinin-added LHRH derivative nasal powder, the powder was administered to three normal human volunteers in the same way as in Example 3, then after a certain time the concentration of LH in the plasma was measured. The results are shown in Fig. 3.
  • Salmon calcitonin in an amount of 40 ⁇ g, rotraxate hydrochloride 40 ⁇ g, microcrystalline cellulose 30 mg, and magnesium stearate 15 ⁇ g were mixed in a mortar and mix to prepare a rotraxate hydrochloride-added calcitonin nasal powder.
  • the powder was weighed to give 100 IU (20 ⁇ g) of calcitonin and was packed in No. 2 capsules, then was administered in the right nasal cavity of three normal human volunteers by a Publizer (registered trademark, Teijin). After administration, 5 ml of blood was taken from a vein in the forearm every certain period and the concentration of salmon calcitonin in the plasma was measured by the RIA method.
  • the results are shown in Fig. 4 by the time curve of the concentration of salmon calcitonin in the plasma together with the results of Comparative Examples 1 and 2.
  • Salmon calcitonin in an amount of 40 ⁇ g, mafenide acetate 60 ⁇ g, microcrystalline cellulose 30 mg, and magnesium stearate 15 ⁇ g were mixed in a mortar to prepare a mafenide acetate-added calcitonin nasal powder.
  • the powder was weighed to give 100 IU (20 ⁇ g) of calcitonin and was packed in No. 2 capsules, then was administered in the right nasal cavity of three normal human volunteers by a Publizer (registered trademark). After administration, 5 ml of blood was taken from a vein in the forearm every certain period of 5 minutes, 15 minutes, 30 minutes, and 60 minutes, and the concentration of salmon calcitonin in the plasma was measured by the RIA method. The results are shown in Fig. 5 by the time curve of the concentration of salmon calcitonin in the plasma.
  • Example 5 The same procedure was followed as in Example 5, except that use was made of 50 ⁇ g of dopamine hydrochloride instead of 60 ⁇ g of mafenide acetate, to prepare a dopamine hydrochloride-added calcitonin nasal powder.
  • the powder was weighed to give 100 IU (20 ⁇ g) of calcitonin and was packed in No. 2 capsules, then was administered to three normal human volunteers in the same way as in Example 5, then after a certain time the concentration of salmon calcitonin in the plasma was measured. The results are shown together with the results of the above-mentioned Comparative Examples 1 and 2 in Fig. 5.
  • a peptide proteinaceous drug nasal powder composition which is improved in absorbency and a peptide proteinaceous drug nasal powder composition which is improved in absorbency and safe to the body.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Physics & Mathematics (AREA)
  • Thermal Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Birds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Claims (19)

  1. Pulver zur nasalen Verarbreichung mit einem proteinartigen Peptid-Medikament, umfassend (i) einen Absorptionsbeschleuniger, umfassend eine Verbindung oder deren Salz, welche in dem Verbindungsmolekül eine Gruppe aufweist gemäß der Formel (II):
    Figure 00330001
    worin das Symbol
    Figure 00330002
    einen Cyclohexanring oder einen Benzolring bedeutet; und worin n eine ganze Zahl von 1 oder 2 ist; worin R1, R2 und R3 unabhängig voneinander ein Mitglied sind, ausgewählt aus der Gruppe, welche besteht aus einem Wasserstoffatom, -COOR, -COR, -OR' und -SO2NH2, und welches substituiert sein kann; vorausgesetzt, dass mindestens ein Rest von R1, R2 oder R3 ein Wasserstoffatom ist; worin R ein Wasserstoffatom, eine niedere C1-C6-Alkylgruppe, welche substituiert sein kann, oder
    Figure 00330003
    repräsentiert; worin R' ein Wasserstoffatom, eine niedere C1-C6-Alkylgruppe, welche substituiert sein kann, eine Phenylgruppe, die substituiert sein kann oder eine C7-C8-Aralkylgruppe repräsentiert, welche substituiert sein kann; und (ii) eine therapeutisch wirksame Menge eines proteinartigen Peptid-Medikamentes.
  2. Nasal zu verabreichende Pulverzusammensetzung nach Anspruch 1, worin die zyklische Struktur ein Cyclohexanring ist und n = 1 in der Formel (II) ist.
  3. Nasal zu verabreichende Pulverzusammensetzung nach Anspruch 2, worin der Cyclohexanring mit einer Gruppe substituiert ist, welche ausgewählt ist aus der aus einem Wasserstoffatom, -CO-C6H4-(CH2)2COOH, einer Carboxylgruppe und -COO-C6H4-(CH2)2COOH bestehenden Gruppe.
  4. Nasal zu verabreichende Pulverzusammensetzung nach Anspruch 2, worin R1 und R3 in Formel (II) Wasserstoffatome sind und R2 -COO-C6H4-(CH2)2COOH bedeutet.
  5. Nasal zu verabreichende Pulverzusammensetzung nach Anspruch 2, worin R1 und R2 in Formel (II) Wasserstoffatome sind und R2 -CO-C6H4-(CH2)2COOH bedeutet.
  6. Nasal zu verabreichende Pulverzusammensetzung nach Anspruch 2, worin R1 und R3 in Formel (II) Wasserstoffatome sind und R2 eine Carboxylgruppe ist.
  7. Nasal zu verabreichende Pulverzusammensetzung nach Anspruch 1, worin die zyklische Struktur in Formel (II) ein Benzolring ist.
  8. Nasal zu verabreichende Pulverzusammensetzung nach Anspruch 7, worin der Benzolring mit einer Gruppe substituiert ist, welche ausgewählt ist aus der aus einem Wasserstoffatom, einer Carboxylgruppe, einer Hydroxylgruppe und einer Sulfamingruppe bestehenden Gruppe.
  9. Nasal zu verabreichende Pulverzusammensetzung nach Anspruch 7, worin R1 und R3 in Formel (II) Wasserstoffatome sind und R2 eine Carboxylgruppe ist und n = 1 ist.
  10. Nasal zu verabreichende Pulverzusammensetzung nach Anspruch 7, worin R1 und R3 in Formel (II) Wasserstoffatome sind, worin R2 eine Sulfamingruppe ist und n = 1 ist.
  11. Nasal zu verabreichende Pulverzusammensetzung nach Anspruch 7, worin in Formel (II) R1 ein Wasserstoffatom ist und worin R2 und R3 Hydroxylgruppen sind und n = 2 ist.
  12. Nasal zu verabreichende Pulverzusammensetzung nach Anspruch 1, worin das proteinartige Peptid-Medikament mindestens ein proteinartiges Peptid-Medikament ist, ausgewählt aus der Gruppe, welche besteht aus Calcitoninen, Insulinen, Somatostatin (GIF) und seinen Derivaten, Parathyroidhormonen (PTH), Substanz P, von Blutplättchen abgeleiteten Wachstumsfaktoren (PDGF), Galanin, Gastrin, Neurokininen, Interleukinen, Neurotensin, Endoserin, Wachstumshormonen (GH), Wachstumshormon freisetzendem Hormon (GHRH) und seinen Derivaten, Wachtstumshormon freisetzendem Faktor (GRF), Lutropin-Follitropin freisetzendem Hormon (LH-FSH-RH) und seinem Derivat, Enkephalin und seinen Derivaten, Sekretin, Bradykinin und seinem Derivat, adrenocorticotrophem Hormon (ACTH) und seinen Derivaten, Glukagon, Insulinwachstumsfaktor (IGF), Calcitonin-Gen verwandtem Peptid (CGRP), Interferonen, Vasopressin und seinen Derivaten, Atrial-Natrium-Peptid (ANP), Erythropoietin, Granulocyten-Kolonie stimulierendem Faktor (G-CSF), und Makrophagen-Kolonie stimulierendem Faktor (M-CSF).
  13. Nasal zu verabreichende Pulverzusammensetzung nach Anspruch 1, worin das proteinartige Peptidmedikament mindestens ein proteinartiges Peptid-medikament ist, ausgewählt aus der Gruppe, welche besteht aus Calcitoninen, Insulinen, Somatostatin (GIF) und seinen Derivaten, Parathyroidhormonen (PTH), Substanz P, von Blutplättchen abgeleiteten Wachstumsfaktoren (PDGF), Wachstumshormon freisetzendem Hormon (GHRH) und seinen Derivaten, Lutropin-Follitropin freisetzendem Hormon (LH-FSH-RH) und seinem Derivat, adrenocorticotrophem Hormon (ACTH) und seinen Derivaten, Glukagon und Calcitonin-Gen verwandtem Peptid (CGRP).
  14. Nasal zu verabreichende Pulverzusammensetzung nach Anspruch 1, worin das proteinartige Peptidmedikament mindestens ein proteinartiges Peptid-medikament ist, ausgewählt aus der Gruppe, welche besteht aus natürlichem Calcitonin und dessen Derivaten des Lachses, des Aales, des Menschen, des Schweines und des Huhns.
  15. Nasal zu verabreichende Pulverzusammensetzung nach Anspruch 1, worin das proteinartige Peptidmedikament mindestens ein proteinartiges Peptid-medikament ist, welches ausgewählt ist aus der Gruppe, welche besteht aus natürlichem Somatostatin und dessen Derivaten des Menschen, der Ratte und des Schweins.
  16. Nasal zu verabreichende Pulverzusammensetzung nach Anspruch 1, worin das proteinartige Peptidmedikament mindestens ein proteinartiges Peptid-medikament ist, welches ausgewählt ist aus der Gruppe, welche besteht aus natürlichem Parathyroidhormon (PTH) und dessen Derivaten des Rindes, des Menschen und der Ratte.
  17. Nasal zu verabreichende Pulverzusammensetzung nach Anspruch 1, worin das proteinartige Peptidmedikament mindestens ein proteinartiges Peptid-medikament ist, welches ausgewählt ist aus der Gruppe, welche besteht aus natürlichem Lutropin-Follitropin freisetzendem Hormon (LH-FSH-RH) und dessen Derivaten des Rindes, des Menschen, der Ratte und des Schweins.
  18. Nasal zu verabreichende Pulverzusammensetzung nach Anspruch 1, worin das proteinartige Peptidmedikament mindestens ein proteinartiges Peptid-medikament ist, welches ausgewählt ist aus der Gruppe, welche besteht aus natürliches Wachstumshormon freisetzenden Hormonen (GHRH) und deren Derivate des Menschen, der Ratte und des Schweins.
  19. Verwendung einer Zusammensetzung, umfassend (i) einen Absorptionsbeschleuniger, umfassend eine Verbindung oder deren Salz, welche in dem Verbindungsmolekül eine Gruppe aufweist gemäß Formel (II):
    Figure 00370001
    worin das Symbol
    Figure 00370002
    einen Cyclohexanring oder einen Benzolring bedeutet; und worin n eine ganze Zahl von 1 oder 2 ist; worin R1, R2 und R3 unabhängig voneinander ein Mitglied sind, ausgewählt aus der Gruppe, welche besteht aus einem Wasserstoffatom, -COOR, -COR, -OR' und -SO2NH2, und welches substituiert sein kann; vorausgesetzt, dass mindestens ein Rest von R1, R2 oder R3 ein Wasserstoffatom ist; worin R ein Wasserstoffatom, eine niedrige C1-C6-Alkylgruppe, welche substituiert sein kann, oder
    Figure 00370003
    repräsentiert; worin R' ein Wasserstoffatom, eine niedere C1-C6-Alkylgruppe, welche substituiert sein kann, eine Phenylgruppe, die substituiert sein kann oder eine C7-C8-Aralkylgruppe, welche substituiert sein kann; repräsentiert und (ii) eine therapeutisch wirksame Menge eines proteinartigen Peptid-Medikamentes zur Zubereitung einer nasal zu verabreichenden Pulverzusammensetzung mit einem proteinartigen Peptidmedikament.
EP94921840A 1993-07-30 1994-07-29 Pulver zur nasalen Verabreichung peptidischer oder proteinischer Arzneistoffe Expired - Lifetime EP0667163B1 (de)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
JP20692293 1993-07-30
JP20692293 1993-07-30
JP206922/93 1993-07-30
JP235841/93 1993-08-30
JP23584193 1993-08-30
JP23584193 1993-08-30
JP164494 1994-01-12
JP164494 1994-01-12
JP1644/94 1994-01-12
PCT/JP1994/001257 WO1995003818A1 (fr) 1993-07-30 1994-07-29 Poudre permettant l'administration par voie nasale d'un medicament peptidique ou proteique

Publications (3)

Publication Number Publication Date
EP0667163A1 EP0667163A1 (de) 1995-08-16
EP0667163A4 EP0667163A4 (de) 2000-04-19
EP0667163B1 true EP0667163B1 (de) 2002-04-03

Family

ID=27275015

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94921840A Expired - Lifetime EP0667163B1 (de) 1993-07-30 1994-07-29 Pulver zur nasalen Verabreichung peptidischer oder proteinischer Arzneistoffe

Country Status (9)

Country Link
US (1) US5578324A (de)
EP (1) EP0667163B1 (de)
JP (1) JP2974412B2 (de)
KR (1) KR100327563B1 (de)
AT (1) ATE215377T1 (de)
CA (1) CA2145302C (de)
DE (1) DE69430295T2 (de)
ES (1) ES2171459T3 (de)
WO (1) WO1995003818A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
WO1995033474A1 (fr) * 1994-06-03 1995-12-14 Tsumura & Co. Composition medicinale
JP3263598B2 (ja) * 1995-11-01 2002-03-04 有限会社ドット 経鼻吸収用生理活性ペプチド組成物
KR100568436B1 (ko) * 1996-02-27 2007-04-25 데이진 가부시키가이샤 분말상경비투여조성물
CN1160127C (zh) * 1998-08-26 2004-08-04 帝人株式会社 粉状经鼻组合物
US7439063B2 (en) * 2002-06-11 2008-10-21 Burnham Institute For Medical Research Neuroprotective synergy of erythropoietin and insulin-like growth factors
WO2004084859A2 (en) * 2003-03-21 2004-10-07 Nastech Pharmaceutical Company Inc. Nasal calcitonin formulations containing chlorobutanol
JP2008019245A (ja) * 2006-06-15 2008-01-31 Japan Science & Technology Agency ヒューマニン誘導体又は該誘導体と神経向性ペプチドとの融合ペプチドを有効成分として含有する、アルツハイマー病予防・治療用の経鼻投与剤
EP3545944B1 (de) * 2016-11-28 2022-12-28 Pola Chemical Industries Inc. Faltenlinderungsmittel
JP7102658B2 (ja) * 2018-05-29 2022-07-20 ポーラ化成工業株式会社 美白用組成物
JP7102657B2 (ja) * 2018-05-29 2022-07-20 ポーラ化成工業株式会社 シワ改善用組成物
BR112020023802B1 (pt) * 2018-05-29 2023-10-31 Pola Chemical Industries, Inc Agente iluminador de pele

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4258030A (en) * 1979-03-07 1981-03-24 Zeria-Shinyaku Kogyo Kabushiki Kaisha Urokinase preparation for oral administration
DE3514508A1 (de) * 1985-04-22 1986-10-30 Kailash Kumar Prof. Dr. 2359 Lentföhrden Gauri Verwendung von dopamin und dessen ester bei der behandlung von glaukom
JPH01308235A (ja) * 1988-06-03 1989-12-12 Yamanouchi Pharmaceut Co Ltd ヒト成長ホルモン経鼻剤
GB9013448D0 (en) * 1990-06-15 1990-08-08 Sandoz Ltd Pharmaceutical resorption-improved somatostatin compositions,their preparation and use
JPH04235923A (ja) * 1991-01-16 1992-08-25 Kyowa Hakko Kogyo Co Ltd 経鼻投与用製剤
JPH04300817A (ja) * 1991-03-27 1992-10-23 Shiseido Co Ltd 口腔用組成物
JPH0558908A (ja) * 1991-09-05 1993-03-09 Mitsubishi Kasei Corp カルシトニン点鼻用医薬組成物
JP3090353B2 (ja) * 1991-09-17 2000-09-18 旭化成工業株式会社 パラチロイドホルモン類含有経鼻投与用乳剤
JP3047948B2 (ja) * 1992-12-07 2000-06-05 株式会社ツムラ ペプチド類経鼻投与用組成物

Also Published As

Publication number Publication date
US5578324A (en) 1996-11-26
WO1995003818A1 (fr) 1995-02-09
CA2145302A1 (en) 1995-02-09
KR100327563B1 (ko) 2002-08-24
EP0667163A4 (de) 2000-04-19
ES2171459T3 (es) 2002-09-16
CA2145302C (en) 2008-10-28
DE69430295T2 (de) 2002-10-31
EP0667163A1 (de) 1995-08-16
ATE215377T1 (de) 2002-04-15
DE69430295D1 (de) 2002-05-08
KR950703352A (ko) 1995-09-20
JP2974412B2 (ja) 1999-11-10

Similar Documents

Publication Publication Date Title
US5482706A (en) Transmucosal therapeutic composition
EP0667163B1 (de) Pulver zur nasalen Verabreichung peptidischer oder proteinischer Arzneistoffe
JP3549542B2 (ja) 経口用ペプチド薬剤
TAMAI et al. In vitro and in vivo inhibition of cysteine proteinases by EST, a new analog of E-64
JPH0741428A (ja) ペプチド、蛋白質性薬物経鼻・経肺製剤
JP5544169B2 (ja) フェニルアルキルカルボン酸誘導体送達剤
KR20010018158A (ko) 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
JP2003519667A (ja) トリグリセリドレベルの調節および脂質異常血症の治療のためのエキセンジンおよびそのアゴニストの使用
WO2006076692A1 (en) Compositions for buccal delivery of parathyroid hormone
JPH03275633A (ja) 生理活性ポリペプチドの吸収促進剤
KR20210093958A (ko) 미토콘드리아 질환을 표적으로 하는 유사체
JPH0592996A (ja) 心房性ナトリウム利尿因子活性をもつペプチド
JPS61126014A (ja) 経鼻投与用水性液剤
JP3009911B2 (ja) ペプチド又は蛋白の内服用新規製剤
CA2492378A1 (en) Modified amino acid for the inhibition of platelet aggregation
JPH0480008B2 (de)
Ha et al. Delivery of peptide and protein drugs
JPH07206699A (ja) ペプチド、蛋白質性薬物経鼻製剤
JPH09309843A (ja) ヒアルロン酸含有経肺投与用製剤
JPH06321804A (ja) カルシトニン類経鼻製剤
WO2006006674A1 (ja) Pthを含有する経粘膜投与剤
JP6222779B2 (ja) 心血管治療法
JPH069424A (ja) 経粘膜用製剤
JPH03120229A (ja) カルシトニン鼻腔内投与剤
KR20070031425A (ko) Ｐｔｈ를 함유하는 경점막 투여제

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950607

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE ES FR GB IT LI NL SE

RHK1 Main classification (correction)

Ipc: A61K 38/00

K1C1 Correction of patent application (title page) published

Effective date: 19950816

RBV Designated contracting states (corrected)

Designated state(s): AT BE CH DE ES FR GB IT LI NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 20000307

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE ES FR GB IT LI NL SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 38/00 A, 7A 61K 38/23 B, 7A 61K 38/28 B, 7A 61K 38/08 B, 7A 61K 38/04 B, 7A 61K 38/27 B, 7A 61K 38/26 B, 7A 61K 38/21 B, 7A 61K 47/18 B, 7A 61K 47/20 B, 7A 61K 9/00 B, 7A 61K 38/09 B, 7A 61K 38/25 B

17Q First examination report despatched

Effective date: 20001123

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE ES FR GB IT LI NL SE

REF Corresponds to:

Ref document number: 215377

Country of ref document: AT

Date of ref document: 20020415

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 69430295

Country of ref document: DE

Date of ref document: 20020508

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BUGNION S.A.

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2171459

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20030106

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20090626

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20090703

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20090623

Year of fee payment: 16

Ref country code: CH

Payment date: 20090706

Year of fee payment: 16

Ref country code: AT

Payment date: 20090702

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20090702

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20090721

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20100723

Year of fee payment: 17

Ref country code: DE

Payment date: 20100728

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20100630

Year of fee payment: 17

BERE Be: lapsed

Owner name: *TEIJIN LTD

Effective date: 20100731

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20110201

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100731

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110201

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100729

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100729

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100731

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20110818

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100730

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20110729

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20120330

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120201

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110801

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69430295

Country of ref document: DE

Effective date: 20120201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110729

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100730